Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Immune Response to Influenza Vaccines in Children
NCT03453801Phase 1Completed
- Sponsor
- Stanford University
- Start
- Sep 2014
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal) and Fluzone Trivalent in influenza (3 arms), sponsored by Stanford University. Primary endpoint: Frequency of antigen-specific T memory phenotype cells at Day 60. Started Sep 2014; status: completed.
02
Drugs
influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03453801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453801.